Prasad Dandawate, PhD

Professional Background

Dr. Dandawate earned a Bachelor and Master of Pharmacy degree with Pharmacology as a specialization, and a Ph.D. in medicinal chemistry from the University of Pune, India. Subsequently, Dr. Dandawate joined Dr. Shrikant Anant's lab at the University of Kansas Medical Center in 2015 as a postdoctoral fellow. He studied the role of prolactin receptor and histone demethylase 3A in pancreatic cancer progression. He is currently working as an Assistant Professor at the Department of Cancer Biology and establishing his research program in gastrointestinal cancers. He is currently studying the role of taste receptor signaling colon and esophageal cancer and the role of KDM3A in pancreatic cancer.

• BS, Pharmacy, University of Pune, Pune, Maharashtra
• MS, Pharmacology, University of Pune, Pune, Maharashtra
• PhD, Chemistry, Savitribai Phule Pune University
• Post Doctoral Fellowship, Cancer Biology, University of Kansas Medical Center, Kansas City, KS

• American Association for Cancer Research , Ad-Hoc Member, 2019 - 2020
• American Pancreatic Association , Ad-Hoc Member, 2017 - 2018
• American Gastroenterological Association , Ad-Hoc Member, 2016 - 2017

---

Research

Overview

Dr. Dandawate's research interest involves understanding key signaling pathways in cancer cells and how targeting these pathways with natural or synthetic compounds as well as the repurposing of FDA-approved drugs will contribute to improved treatment for cancer patients. Many anticancer drugs have the problem of water solubility and metabolic instability and hence use of drug delivery systems especially cyclodextrin-based formulations to overcome these problems is one of his interests. Following are ongoing projects he is working on.

1. Studying the role of taste receptors in the colon and esophageal cancers.

2. Establishing the role of histone demethylase KDM3A in pancreatic cancer.

• Role of Bitter taste receptor TAS2R38 in colorectal cancer, Department of Defense, PI
• The role of KDM3A-STAT3 interaction in pancreatic cancer, American Gastroenterological Society Research Foundation, PI

• Dandawate, P, Kaushik, G, Ghosh, C, Standing, D, Ali Sayed, A., A, Choudhury, S, Subramaniam, D, Manzardo, A, Banerjee, T, Santra, S, Ramamoorthy, P, Butler, M, Padhye, S., B, Baranda, J, Kasi, A, Sun, W, Tawfik, O, Coppola, D, Malafa, M, Umar, S, Soares, M., J, Saha, S, Weir, S., J, Dhar, A, Jensen, R., A, Thomas, S., M, Anant, S. 2019. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.. Gastroenterology
• Dandawate, P, Ghosh, C, Palaniyandi, K, Paul, S, Rawal, S, Pradhan, R, Sayed AAA, Choudhury, S, Standing, D, Subramaniam, D, Padhye, S., B, Gunewardena, S, Thomas, S., M, Neil, M., O, Tawfik, O, Welch, D., R, Jensen, R., A, Maliski, S, Weir, S, Iwakuma, T, Anant, S, Dhar, A. 2019. The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 and Promotes Tumorigenesis in Mice.. Gastroenterology, 157 (6), 1646-1659.e11
• Dandawate, P, Subramaniam, D, Panovich, P, Standing, D, Krishnamachary, B, Kaushik, G, Thomas, S., M, Dhar, A, Weir, S., J, Jensen, R., A, Anant, S. 2020. Cucurbitacin B and I inhibits colon cancer growth by targeting the Notch signaling pathway.. Scientific reports, 10 (1), 1290
• Dandawate, P, Ahmed, K, Padhye, S, Ahmad, A, Biersack, B. 2020. Anticancer Active Heterocyclic Chalcones: Recent Developments.. Anti-cancer agents in medicinal chemistry
• Dandawate, P., R, Subramaniam, D, Padhye, S., B, Anant, S. 2016. Bitter melon: a panacea for inflammation and cancer.. Chinese journal of natural medicines, 14 (2), 81-100
• Ghaisas, M., M, Dandawate, P., R, Zawar, S., A, Ahire, Y., S, Gandhi, S., P. 2010. Antioxidant, antinociceptive and anti-inflammatory activities of atorvastatin and rosuvastatin in various experimental models.. Inflammopharmacology, 18 (4), 169-77
• Dandawate, P., R, Subramaniam, D, Jensen, R., A, Anant, S. 2016. Targeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapy.. Seminars in cancer biology, 40-41, 192-208